Dimensional Fund Advisors
ELVN icon

Dimensional Fund Advisors’s Enliven Therapeutics ELVN Stock Holding History

Dimensional Fund Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1M Sell
671,412
-10,303
-2% -$437K 0.01% 1800
2026
Q1 		$26.7M Buy
681,715
+282,822
+71% +$7.84M 0.01% 1837
2025
Q4 		$6.14M Buy
398,893
+238,434
+149% +$4.75M ﹤0.01% 2462
2025
Q3 		$3.28M Buy
160,459
+113,608
+242% +$2.29M ﹤0.01% 2646
2025
Q2 		$942K Buy
+46,851
New +$887K ﹤0.01% 2901
2023
Q3 		– Sell
-23,762
Closed -$485K – 3482
2023
Q2 		$485K Buy
23,762
+13,847
+140% +$280K ﹤0.01% 3071
2023
Q1 		$217K Buy
+9,915
New +$202K ﹤0.01% 3187
2022
Q3 		$64K Buy
+7,066
New +$41.7K ﹤0.01% 3377

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Dimensional Fund Advisors's ELVN Position: Q2 2026 in Review

Dimensional Fund Advisors reduced its Enliven Therapeutics (ELVN) stake by 1.5% in Q2 2026, selling an estimated $437K and leaving 671,412 shares worth $34.1M. The position accounts for 0.01% of the portfolio, ranked #1800.

Dimensional Fund Advisors first reported a position in ELVN in Q3 2022 and has held it in 8 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Dimensional Fund Advisors held 671,412 shares of Enliven Therapeutics worth $34.1M as of Q2 2026.
  • Dimensional Fund Advisors sold 10,303 Enliven Therapeutics shares in Q2 2026, an estimated $437K.
  • Enliven Therapeutics made up 0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #1800 holding.
  • Dimensional Fund Advisors first reported a position in Enliven Therapeutics in Q3 2022 and has held it in 8 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.